PE20081794A1 - Composicion farmaceutica que comprende un agente calcilitico - Google Patents

Composicion farmaceutica que comprende un agente calcilitico

Info

Publication number
PE20081794A1
PE20081794A1 PE2008000407A PE2008000407A PE20081794A1 PE 20081794 A1 PE20081794 A1 PE 20081794A1 PE 2008000407 A PE2008000407 A PE 2008000407A PE 2008000407 A PE2008000407 A PE 2008000407A PE 20081794 A1 PE20081794 A1 PE 20081794A1
Authority
PE
Peru
Prior art keywords
methyl
isopropyl
oil
pharmaceutical composition
composition including
Prior art date
Application number
PE2008000407A
Other languages
English (en)
Inventor
Thomas Buhl
Oskar Kalb
Elisabete Goncalves
Lorenz Meinel
Sibylle Reidemeister
Agnes Taillardat
Leo Widler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38016483&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081794(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20081794A1 publication Critical patent/PE20081794A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN AGENTE CALCILITICO SELECCIONADO DE 1-ISOPROPIL-4-(4-ISOPROPIL-FENIL)-6-PROPARGILOXI-1H-QUINAZOLIN-2-ONA, 2-(4-ISOPROPIL-FENIL)-7-METOXI-1-(2-METOXI-ETIL)-5-(2-METIL-SULFANIL-PIRIDIN-3-IL-METIL)-4-TRIFLUORO-METIL-1H-BENZOIMIDAZOL, ENTRE OTROS; B) UN VEHICULO COMO HIDROXI-PROPIL-METIL-CELULOSA, UN COMPONENTE LIPOFILICO COMO ESTERES DE ACIDOS GRASOS DE PROPILENGLICOL, UN TENSOACTIVO COMO POLIETILENGLICOL-ACEITE DE RICINO HIDROGENADO Y UN COMPONENTE HIDROFILICO COMO PEG 400, DIMETIL ISOSORBIDE O TRANSCUTOL Y/O UN COSOLVENTE COMO ETANOL. DICHA COMPOSICION SE ENCUENTRA EN FORMA DE CAPSULA GEL O DISPERSION SOLIDA QUE INDUCE A UNA ABSORCION RAPIDA Y DE CORTA DURACION DEL PRINCIPIO ACTIVO Y LIBERACION DE HORMONA PARATIROIDEA
PE2008000407A 2007-03-02 2008-02-29 Composicion farmaceutica que comprende un agente calcilitico PE20081794A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07103365A EP1964548A1 (en) 2007-03-02 2007-03-02 Pharmaceutical compositions comprising a calcilytic agent

Publications (1)

Publication Number Publication Date
PE20081794A1 true PE20081794A1 (es) 2009-01-09

Family

ID=38016483

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000407A PE20081794A1 (es) 2007-03-02 2008-02-29 Composicion farmaceutica que comprende un agente calcilitico

Country Status (20)

Country Link
US (1) US20100022565A1 (es)
EP (2) EP1964548A1 (es)
JP (1) JP2010520179A (es)
KR (1) KR20090125245A (es)
CN (1) CN101621993A (es)
AR (1) AR065564A1 (es)
AU (1) AU2008223876A1 (es)
CA (1) CA2678794A1 (es)
CL (1) CL2008000617A1 (es)
CO (1) CO6210808A2 (es)
EC (1) ECSP099611A (es)
GT (1) GT200900235A (es)
IL (1) IL200274A0 (es)
MA (1) MA31201B1 (es)
MX (1) MX2009009343A (es)
PE (1) PE20081794A1 (es)
TN (1) TN2009000358A1 (es)
TW (1) TW200843762A (es)
WO (1) WO2008107390A1 (es)
ZA (1) ZA200905472B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606426D0 (en) * 2006-03-30 2006-05-10 Novartis Ag Benzimidazole derivatives
JP2010505811A (ja) 2006-10-04 2010-02-25 ファイザー・プロダクツ・インク カルシウム受容体アンタゴニストとしてのピリド［４，３−ｄ］ピリミジン−４（３Ｈ）−オン誘導体
CA2913731C (en) * 2013-06-04 2021-05-25 Monosol Llc Water-soluble film sealing solutions, related methods, and related articles
EP3458015A4 (en) * 2016-05-20 2020-02-19 Azure Biotech, Inc. VAGINAL ADMINISTRATION SYSTEMS WITH SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM) AND USES THEREOF
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
KR102220255B1 (ko) * 2019-08-13 2021-02-26 동국대학교 산학협력단 수술 후 부갑상선기능저하증 개선 또는 치료용 약학 조성물 및 이를 이용한 치료 방법
WO2021029517A1 (en) * 2019-08-13 2021-02-18 Dongguk University Industry-Academic Cooperation Foundation Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same
IL300285A (en) * 2020-08-04 2023-04-01 Calcilytix Therapeutics Inc Formulations of triphenyl calcilytic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202261B2 (en) * 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
PE20001456A1 (es) * 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
JP2006512315A (ja) * 2002-11-04 2006-04-13 エヌピーエス ファーマスーティカルズ インコーポレイテッド カルシリティックとしてのキナゾリノン化合物

Also Published As

Publication number Publication date
EP2124893A1 (en) 2009-12-02
IL200274A0 (en) 2010-04-29
CL2008000617A1 (es) 2008-09-12
CA2678794A1 (en) 2008-09-12
TW200843762A (en) 2008-11-16
TN2009000358A1 (en) 2010-12-31
MX2009009343A (es) 2009-09-11
AU2008223876A1 (en) 2008-09-12
ZA200905472B (en) 2010-04-28
CN101621993A (zh) 2010-01-06
AR065564A1 (es) 2009-06-17
ECSP099611A (es) 2009-10-30
US20100022565A1 (en) 2010-01-28
MA31201B1 (fr) 2010-02-01
EP1964548A1 (en) 2008-09-03
WO2008107390A1 (en) 2008-09-12
KR20090125245A (ko) 2009-12-04
JP2010520179A (ja) 2010-06-10
GT200900235A (es) 2010-03-15
CO6210808A2 (es) 2010-10-20

Similar Documents

Publication Publication Date Title
PE20081794A1 (es) Composicion farmaceutica que comprende un agente calcilitico
PE20110449A1 (es) Emulsiones modificadas de liberacion de medicina para aplicacion a la piel o la mucosa vaginal
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
ES2409069B2 (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
PE20080765A1 (es) Formas de dosificacion farmaceutica
CL2009001766A1 (es) Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica.
AR060847A1 (es) Formulacion a base de calendula, aloe y centella.
ECSP099635A (es) Formulaciones líquidas que forman una capa dérmica para la liberación de fármacos a la piel
AR090695A1 (es) Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis
CL2011001177A1 (es) Formulacion inyectable que comprende ceftiofur, alcohol bencilico, propilenglicol, un agente humectante y aceite de semilla de algodon.
AR078247A1 (es) Vacuna de pcsk9
CL2011001621A1 (es) Composicion farmaceutica oral de liberacion sostenida que comprende en una forma de dosificacion unitaria, una matriz hidrofilica, un opioide, una sal de un aine, y opcionalmente un surfactante aniónico; y uso para preparar medicamentos utiles en la prevencion, alivio o disminución del nivel del dolor y supresión de la tos.
PE20120322A1 (es) Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
PE20142192A1 (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina ii y/o diuretico
PE20110642A1 (es) Formulaciones antifungicas topicas a base de terbinafina y compuestos similares a terbinafina y metodos de uso
CL2012003038A1 (es) Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia.
NI200800175A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias.
AR073901A1 (es) Composicion topica farmaceutica, unguento y cremas que la comprende, y sus usos
PE20070430A1 (es) Composiciones topicas que comprenden o-desmetilvenlafaxina (odv)
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
AR078194A1 (es) Composicion antiperspirante / desodorante
MY157513A (en) A water-in-oil type emulsion for treating a disease of the eye
AR088072A1 (es) Articulo absorbente

Legal Events

Date Code Title Description
FD Application declared void or lapsed